|
rs779848635
|
|
|
0.010 |
GeneticVariation |
BEFREE |
P21 Ser31Arg and FGFR2 rs2981582 Polymorphisms as Risk Factors for Early Onset of Breast Cancer in Yogyakarta, Indonesia.
|
31759353 |
2019 |
|
rs10736303
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In the validation study using Stage I of the 2,273 cases and 2,052 controls, seven GWAS-identified loci [5q11.2/MAP3K1 (rs889312 and rs16886165), 5p15.2/ROPN1L (rs1092913), 5q12/MRPS30 (rs7716600), 6q25.1/ESR1 (rs2046210 and rs3734802), 8q24.21 (rs1562430), 10q26.13/FGFR2 (rs10736303), and 16q12.1/TOX3 (rs4784227 and rs3803662)] were significantly associated with breast cancer risk in Korean women (Ptrend < 0.05).
|
22452962 |
2012 |
|
rs1296941849
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we evaluated the association of the SNP rs1982073 (Leu10Pro) in transforming growth factor-beta 1 (TGFB1) gene and the SNP rs1219648 in fibroblast growth factor receptor 2 (FGFR2) gene with the risk and aggressiveness of breast cancer among women of Han nationality in North China.
|
20640597 |
2011 |
|
rs774554190
|
|
|
0.010 |
GeneticVariation |
BEFREE |
In this study, we evaluated the association of the SNP rs1982073 (Leu10Pro) in transforming growth factor-beta 1 (TGFB1) gene and the SNP rs1219648 in fibroblast growth factor receptor 2 (FGFR2) gene with the risk and aggressiveness of breast cancer among women of Han nationality in North China.
|
20640597 |
2011 |
|
rs746116691
|
|
|
0.010 |
GeneticVariation |
BEFREE |
There was no significant association between the risk of breast cancer and FGFR2 (C906T).
|
19469636 |
2009 |
|
rs7895676
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Thus, in addition to the confirmation of association of FGFR2 with the BC risk in this new population, our study has suggested that rs7895676 is not likely to represent the causative variant.
|
19536173 |
2009 |
|
rs1078806
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We obtained a significant allele P value of association with AJ breast cancer in the FGFR2 region (P = 1.5 x 10(-5), odds ratio (OR) 1.26, 95% confidence interval (CI) 1.13-1.40 at rs1078806 for all phases combined).
|
18326623 |
2008 |
|
rs35054928
|
|
|
0.710 |
GeneticVariation |
BEFREE |
We confirmed ten risk-associated variants within three reported breast cancer susceptibility loci in a Chinese Han population: 5q11.2 (rs16886181, P = 5.29 × 10(-6), OR = 1.19; rs1017226, P = 5.24 × 10(-4), OR = 1.22; rs16886034, P = 2.00 × 10(-3), OR = 1.21; rs16886113, P = 1.24 × 10(-3), OR = 1.20; rs16886364, P = 9.20 × 10(-4), OR = 1.21; rs16886397, P = 1.17 × 10(-3), OR = 1.20; rs16886448, P = 1.62 × 10(-3,)OR = 1.20; and rs2229882, P = 5.14 × 10(-4), OR = 1.31), 5q14.3 (rs421379, P = 2.83 × 10(-13), OR = 1.83), and 10q26.1 (rs35054928, P = 7.73 × 10(-6), OR = 1.18).
|
27572337 |
2016 |
|
rs2981575
|
|
|
0.710 |
GeneticVariation |
BEFREE |
FGFR2 rs2981575 had the strongest association with breast cancer risk (per allele HR = 1.28, 95% CI 1.18-1.39, ).
|
21060860 |
2010 |
|
rs11200014
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Results from the current meta-analysis indicates that three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene are associated with breast cancer susceptibility and might be a potential biomarkers for breast cancer risk.
|
23124475 |
2012 |
|
rs11200014
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Four SNPs mapped to 10q26.13/FGFR2 were associated with increased breast cancer risk via an additive model with per-allelic risks (95 % CI) of 1.26 (1.12-1.43) at rs1219648, 1.22 (1.07-1.38) at rs2981582, 1.21 (1.07-1.36) at rs2981579, and 1.18 (1.04-1.35) at rs11200014.
|
22965832 |
2012 |
|
rs3750817
|
|
|
0.720 |
GeneticVariation |
BEFREE |
In addition, rs3750817 in intron 2 of the fibroblast growth factor receptor 2 gene, which was reported to be associated with breast cancer susceptibility, was significantly replicated with P(combined) of 8.47 × 10(-8) with OR=1.22.
|
22951594 |
2012 |
|
rs3750817
|
|
|
0.720 |
GeneticVariation |
BEFREE |
Postmenopausal women having TT genotype for SNP rs3750817 have a reduced breast cancer risk and seem to experience comparatively favorable effects of postmenopausal hormone therapy.
|
19861516 |
2009 |
|
rs2981579
|
|
|
0.740 |
GeneticVariation |
BEFREE |
This meta-analysis of case-control studies provides strong evidence that fibroblast growth factor 2 (FGFR2; rs11200014, rs2981579, and rs1219648) polymorphisms are significantly associated with the BC risk.
|
29390357 |
2017 |
|
rs2981579
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Four SNPs mapped to 10q26.13/FGFR2 were associated with increased breast cancer risk via an additive model with per-allelic risks (95 % CI) of 1.26 (1.12-1.43) at rs1219648, 1.22 (1.07-1.38) at rs2981582, 1.21 (1.07-1.36) at rs2981579, and 1.18 (1.04-1.35) at rs11200014.
|
22965832 |
2012 |
|
rs2981579
|
|
|
0.740 |
GeneticVariation |
BEFREE |
Results from the current meta-analysis indicates that three novel functional polymorphisms (rs11200014, rs2981579, and rs2981578) in the promoter of FGFR2 gene are associated with breast cancer susceptibility and might be a potential biomarkers for breast cancer risk.
|
23124475 |
2012 |
|
rs2981579
|
|
|
0.740 |
GeneticVariation |
BEFREE |
A dose-dependent association was observed between the risk of breast cancer and the genetic risk score, which was an aggregate measure of alleles in seven selected variants, namely FGFR2-rs2981579, TOX3/TNRC9-rs3803662, C6orf97-rs2046210, 8q24-rs13281615, SLC4A7-rs4973768, LSP1-rs38137198, and CASP8-rs10931936.
|
22160591 |
2012 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
This meta-analysis of case-control studies provides strong evidence that FGFR2 (rs2981582, rs2420946 and rs2981578) polymorphisms were significantly associated with the BC risk.
|
27966449 |
2017 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Significant associations with breast cancer risk were observed for rs2420946, rs2981579, and rs2981582 with OR (95% CI) per risk allele of 1.19 (1.03-1.39), 1.24 (1.07-1.43), and 1.17 (1.01-1.36), respectively.
|
26421298 |
2015 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
To investigate this inconsistency, we performed a meta-analysis of 37 studies involving a total of 288,142 subjects for rs2981582, rs1219648, and rs2420946 polymorphism of the FGFR2 gene to evaluate the effect of FGFR2 on genetic susceptibility for BC.
|
23184080 |
2013 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In the haplotype analysis, the FGFR2 rs2981582 T / rs2420946 T / rs1219648 G haplotype (ht2) was associated with a significantly increased BC risk compared with the rs2981582 C / rs2420946 C / rs1219648 A haplotype in familial BC and in non-familial early-onset BC (OR = 1.32, 95 % CI 1.06-1.65, P = 0.012; OR = 1.46, 95 % CI 1.11-1.91, P = 0.004, respectively).
|
23225170 |
2013 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Three commonly studied FGFR2 polymorphisms including rs1219648 (A > G), rs2420946 (C > T), and rs2981582 (C > T) were selected to explore their association with risk of development of breast cancer by meta-analysis of published case-control studies.
|
20300826 |
2010 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In conclusion, this meta-analysis suggests that rs2981582, rs1219648, and rs2420946 polymorphisms in FGFR2 are associated with elevated BC risk.
|
20364400 |
2010 |
|
rs2420946
|
|
|
0.770 |
GeneticVariation |
BEFREE |
We observed a statistically significant association between 4 SNPs and breast cancer risk and these 4 SNPs were in strong linkage disequilibrium in the Japanese population. rs2420946 was associated with a population-attributable risk of 17.7%.
|
19582883 |
2009 |
|
rs2981578
|
|
|
0.790 |
GeneticVariation |
BEFREE |
The results suggest these polymorphisms, especially rs1966265 and rs2981578, might be candidate pharmacogenomics factors to the response and prognosis prediction for individualized CET-based chemotherapy in breast cancer patients.
|
30359238 |
2018 |